Scholar Rock/$SRRK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Ticker
- $SRRK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Cambridge, United States
- Website
- www.scholarrock.com
Scholar Rock Metrics
BasicAdvanced
$4.9B
-
-$3.36
0.68
-
Price and volume
Market cap
$4.9B
Beta
0.68
52-week high
$61.76
52-week low
$27.07
Average daily volume
2.1M
Financial strength
Current ratio
7.021
Quick ratio
6.812
Long term debt to equity
0.778
Total debt to equity
0.778
Interest coverage (TTM)
-38.02%
Profitability
EBITDA (TTM)
-404.883
Management effectiveness
Return on assets (TTM)
-58.82%
Return on equity (TTM)
-167.77%
Valuation
Price to book
19.47
Price to tangible book (TTM)
19.47
Price to free cash flow (TTM)
-16.639
Free cash flow yield (TTM)
-6.01%
Free cash flow per share (TTM)
-2.443
Growth
Earnings per share change (TTM)
2.18%
3-year earnings per share growth (CAGR)
5.05%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Analyst projections of the future price of Scholar Rock stock.
Bulls say / Bears say
The FDA has approved ISEMBYLD for adults and children aged two and over who are receiving SMN2-targeted treatment, making it an approved add-on option for SMA. In the pivotal trial, 34.2% of treated children achieved a clinically meaningful motor-function gain versus 13.5% on placebo. (FDA)
Apitegromab could expand beyond SMA: dosing has begun in a Phase 2 trial for facioscapulohumeral muscular dystrophy, and the FDA has granted Fast Track and Orphan Drug designations. This remains an early-stage opportunity, but it could open a second rare-disease market. (BioSpace)
Scholar Rock says it has aligned with Japan’s regulator to submit an apitegromab application by year-end. A Japanese approval could broaden the market beyond the US, although the application has not yet been filed. (Scholar Rock)
The FDA observed an increased risk of fractures, including serious fractures, and warns that ISEMBYLD may cause fetal harm and affect reproductive function. These risks could make treatment and monitoring less straightforward. (FDA)
Scholar Rock withdrew its European application after a manufacturing site received an FDA inspection classification of Official Action Indicated, and plans to resubmit using another facility. This delays access to a major market and leaves manufacturing execution as a risk beyond the US approval. (Scholar Rock)
Scholar Rock reported a $109.9 million net loss in Q2 and raised $62.8 million through its at-the-market share programme. Continued heavy spending could mean further borrowing or dilution if commercial uptake does not build quickly. (Scholar Rock)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Upcoming events
No upcoming events
Scholar Rock News
AllArticlesVideos
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire3 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire4 weeks ago
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Benzinga1 month ago
Funds containing Scholar Rock
AllUSDGBPEUR
Fund name | Fund size | $SRRK weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.33% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.33% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.15% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.15% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.